Trial intelligence / Profile preview

LW402 in Moderate-to-Severe Active Rheumatoid Arthritis

CTR20222944Phase 2Completed

Sponsor
Shanghai Changsen Pharmaceutical
Start
Nov 2022
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of lw402 in rheumatoid arthritis (RA), sponsored by Shanghai Changsen Pharmaceutical. Started Nov 2022; status: completed.

02

Drugs

lw402
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on CTR20222944.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20222944.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call